RxDoctor Payments Data

Alexander Sweidan, MD

Pulmonary Disease · Costa Mesa, CANPI 1689070161

Payments from drug & device makers

$13,836in general payments, 2019–2025

Across 452 payments — averaging $30.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Pulmonx Corporation$1K
  • GSK$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Boehringer Ingelheim$611
  • Mylan Specialty L.p.$588
  • plus $6K from 32 others

What the payments were for

  • Speaking & faculty fees$1,40010%
  • Travel & lodging$1,2009%
  • Food & beverage$11,04880%
  • Education$1881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,836 in reported general payments places this provider in the 80th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$1,080,440
Medicare patients
1,442
Services billed
9,589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate28$376,939
Trelegy ElliptaFluticasone/Umeclidin/Vilanter494$352,640
Breztri AerosphereBudesonide/Glycopyr/Formoterol100$78,394
Breo ElliptaFluticasone/Vilanterol159$76,768
NucalaMepolizumab12$43,036
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr69$37,690
Spiriva RespimatTiotropium Bromide31$27,241
XareltoRivaroxaban27$24,035
EliquisApixaban31$21,559
Wixela InhubFluticasone Propion/Salmeterol163$17,101
Fluticasone-SalmeterolFluticasone Propion/Salmeterol109$14,794
Albuterol Sulfate HfaAlbuterol Sulfate277$12,071
Combivent RespimatIpratropium/Albuterol Sulfate20$10,530
DuleraMometasone/Formoterol25$9,424
Spiriva HandihalerTiotropium Bromide19$9,259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta$1,437$518,717760 claims
Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat$611$414,71179 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$2,530$95,997147 claims
Johnson & JohnsonXarelto$174$24,03527 claims
PfizerEliquis$44$21,55931 claims
MerckDulera$53$9,42425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Costa Mesa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →